Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.

Parimi S, Bondy S, Tsang E, McKenzie MR, Bachand F, Aparicio M, Duncan G, Sunderland K, Olson RA, Pai HH, Alexander AS, LaPointe V, Chi KN, Tyldesley S.

Can Urol Assoc J. 2019 Feb 7. doi: 10.5489/cuaj.5685. [Epub ahead of print]

PMID:
31364977
2.

A Prospective Study on 18F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer.

Rousseau E, Wilson D, Lacroix-Poisson F, Krauze A, Chi K, Gleave M, McKenzie M, Tyldesley S, Goldenberg SL, Bénard F.

J Nucl Med. 2019 Apr 12. pii: jnumed.119.226381. doi: 10.2967/jnumed.119.226381. [Epub ahead of print]

PMID:
30979820
3.

A Population-Based Study of Palliative Radiation Therapy for Bone Metastases in Patients Dying of Prostate Cancer.

Cho CJ, Sunderland K, Pickles T, Bachand F, Chi KN, Tyldesley S.

Pract Radiat Oncol. 2019 May;9(3):e274-e282. doi: 10.1016/j.prro.2019.01.002. Epub 2019 Jan 11.

PMID:
30641243
4.

Pathologically Node-Positive Prostate Carcinoma - Prevalence, Pattern of Care and Outcome From a Population-Based Study.

Roy S, Sia M, Tyldesley S, Bahl G.

Clin Oncol (R Coll Radiol). 2019 Feb;31(2):91-98. doi: 10.1016/j.clon.2018.10.005. Epub 2018 Oct 30.

PMID:
30389262
5.

Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5.

Olson R, Liu M, Bergman A, Lam S, Hsu F, Mou B, Berrang T, Mestrovic A, Chng N, Hyde D, Matthews Q, Lund C, Glick D, Pai H, Basran P, Carolan H, Valev B, Lefresene S, Tyldesley S, Schellenberg D.

BMC Cancer. 2018 Oct 4;18(1):954. doi: 10.1186/s12885-018-4859-7.

6.

Programmatic Comparison and Dissemination of an Audit of Single-fraction Radiation Therapy Prescribing Practices for Bone Metastases is Associated with a Meaningful and Lasting Change in Practice on a Population Level.

Olson R, Chan M, Minhas N, Kandola G, Tiwana M, Lefresne S, Halperin R, Schellenberg D, Wai E, Ahmed N, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):325-329. doi: 10.1016/j.ijrobp.2018.06.001. Epub 2018 Jun 11.

PMID:
29902558
7.

Close Margins Less Than 2 mm Are Not Associated With Higher Risks of 10-Year Local Recurrence and Breast Cancer Mortality Compared With Negative Margins in Women Treated With Breast-Conserving Therapy.

Tyler S, Truong PT, Lesperance M, Nichol A, Baliski C, Warburton R, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2018 Jul 1;101(3):661-670. doi: 10.1016/j.ijrobp.2018.03.005. Epub 2018 Mar 13.

PMID:
29678525
8.

Impact of the Spinal Instability Neoplastic Score on Surgical Referral Patterns and Outcomes.

Dosani M, Lucas S, Wong J, Weir L, Lomas S, Cumayas C, Fisher C, Tyldesley S.

Curr Oncol. 2018 Feb;25(1):53-58. doi: 10.3747/co.25.3835. Epub 2018 Feb 28.

9.

The TEACHH model to predict life expectancy in patients presenting for palliative spine radiotherapy: external validation and comparison with alternate models.

Dosani M, Tyldesley S, Bakos B, Hamm J, Kong T, Lucas S, Wong J, Liu M, Hamilton S.

Support Care Cancer. 2018 Jul;26(7):2217-2227. doi: 10.1007/s00520-018-4064-x. Epub 2018 Feb 1.

PMID:
29392478
10.

A population-based study of the use of radium 223 in metastatic castration-resistant prostate cancer: Factors associated with treatment completion.

Parimi S, Tsang E, Alexander A, Mckenzie M, Bachand F, Sunderland K, Chi KN, Aparicio M, Worsley D, Tyldesley S.

Can Urol Assoc J. 2017 Oct;11(10):350-355. doi: 10.5489/cuaj.4415.

11.

Provincial development of a patient-reported outcome initiative to guide patient care, quality improvement, and research.

Olson RA, Howard F, Lapointe V, Schellenberg D, Nichol A, Bowering G, Curtis S, Walter A, Brown S, Thompson C, Bergin J, Lomas S, French J, Halperin R, Tyldesley S, Beckham W.

Healthc Manage Forum. 2018 Jan;31(1):13-17. doi: 10.1177/0840470417715478.

PMID:
29264976
12.

Assessing Health Implications of the Potential Radiation Exposure in the Community During Pregnancy: A Case Study.

Wong J, Clark H, Corns R, Tyldesley S.

Cureus. 2017 Oct 12;9(10):e1770. doi: 10.7759/cureus.1770.

13.

Signed family physician reminder letters to women overdue for screening mammography: A randomized clinical trial.

Chan EK, Wilson C, Tyldesley S, Olivotto IA, Lai A, Sam J, Harry R, Nichol A.

J Med Screen. 2018 Sep;25(3):149-154. doi: 10.1177/0969141317719921. Epub 2017 Nov 20.

PMID:
29157121
14.

Estimating prognosis at the time of repeat whole brain radiation therapy for multiple brain metastases: The reirradiation score.

Logie N, Jimenez RB, Pulenzas N, Linden K, Ciafone D, Ghosh S, Xu Y, Lefresne S, Wong E, Son CH, Shih HA, Wong WW, Tyldesley S, Dennis K, Chow E, Fairchild AM.

Adv Radiat Oncol. 2017 Jun 14;2(3):381-390. doi: 10.1016/j.adro.2017.05.010. eCollection 2017 Jul-Sep.

15.

Neoadjuvant systemic therapy in breast cancer: use and trends in radiotherapy practice.

Koulis TA, Beecham K, Speers C, Tyldesley S, Voduc D, Simmons C, Olson R.

Curr Oncol. 2017 Oct;24(5):310-317. doi: 10.3747/co.24.3558. Epub 2017 Oct 25.

16.

Let "Whitmore's Principle" be the Guide.

Tyldesley S, Schellenberg D.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):766-767. doi: 10.1016/j.ijrobp.2017.03.013. No abstract available.

PMID:
29063844
17.

Brachytherapy for Intermediate-Risk Prostate Cancer, Androgen Deprivation, and the Risk of Death.

Pickles T, Tyldesley S, Hamm J, Virani SA, Morris WJ, Keyes M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):45-52. doi: 10.1016/j.ijrobp.2017.08.042. Epub 2017 Sep 4.

PMID:
29029889
18.

Severe Late Toxicity After Adjuvant Breast Radiotherapy in a Patient with a Germline Ataxia Telangiectasia Mutated Gene: Future Treatment Decisions.

Dosani M, Schrader KA, Nichol A, Sun S, Shenkier T, Lohn Z, Aubertin G, Tyldesley S.

Cureus. 2017 Jul 11;9(7):e1458. doi: 10.7759/cureus.1458.

19.

In Regard to Ciezki et al.

Morris WJ, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):240-242. doi: 10.1016/j.ijrobp.2017.04.035. Epub 2017 Aug 7. No abstract available.

PMID:
28816154
20.

The Relationship between Hot Flashes and Testosterone Recovery after 12 Months of Androgen Suppression for Men with Localised Prostate Cancer in the ASCENDE-RT Trial.

Dosani M, Morris WJ, Tyldesley S, Pickles T.

Clin Oncol (R Coll Radiol). 2017 Oct;29(10):696-701. doi: 10.1016/j.clon.2017.06.009. Epub 2017 Jul 13.

PMID:
28712786
21.

The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapy.

Tran E, Paquette M, Jay J, Hamm J, Liu M, Duncan G, Pickles T, Tyldesley S.

Radiother Oncol. 2017 Aug;124(2):291-295. doi: 10.1016/j.radonc.2017.04.028. Epub 2017 Jul 4.

PMID:
28687398
22.

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study.

Nichol AM, Chan EK, Lucas S, Smith SL, Gondara L, Speers C, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):829-839. doi: 10.1016/j.ijrobp.2017.02.094. Epub 2017 Mar 1.

PMID:
28602413
23.

ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.

Rodda S, Tyldesley S, Morris WJ, Keyes M, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):286-295. doi: 10.1016/j.ijrobp.2017.01.008. Epub 2017 Jan 6.

PMID:
28433432
24.

Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.

Morris WJ, Tyldesley S, Rodda S, Halperin R, Pai H, McKenzie M, Duncan G, Morton G, Hamm J, Murray N.

Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):275-285. doi: 10.1016/j.ijrobp.2016.11.026. Epub 2016 Nov 24.

PMID:
28262473
25.

Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA.

Breast Cancer Res Treat. 2017 Apr;162(2):397-398. doi: 10.1007/s10549-017-4114-y. No abstract available.

PMID:
28110478
26.

Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.

den Brok WD, Speers CH, Gondara L, Baxter E, Tyldesley SK, Lohrisch CA.

Breast Cancer Res Treat. 2017 Feb;161(3):549-556. doi: 10.1007/s10549-016-4080-9. Epub 2016 Dec 20.

PMID:
28000014
27.

Secondary Breast Cancer Risk by Radiation Volume in Women With Hodgkin Lymphoma.

Conway JL, Connors JM, Tyldesley S, Savage KJ, Campbell BA, Zheng YY, Hamm J, Pickles T.

Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):35-41. doi: 10.1016/j.ijrobp.2016.10.004. Epub 2016 Oct 13.

PMID:
27979454
28.

Capacity planning and appointment scheduling for new patient oncology consults.

Ma X, Sauré A, Puterman ML, Taylor M, Tyldesley S.

Health Care Manag Sci. 2016 Dec;19(4):347-361. Epub 2015 Jul 9.

PMID:
26156688
29.

Assessment of Adaptive Margins Using a Single Planning Computed Tomography Scan for Bladder Radiotherapy.

Canlas R, McVicar N, Nakano S, Sahota H, Mahajan P, Tyldesley S.

J Med Imaging Radiat Sci. 2016 Sep;47(3):227-234. doi: 10.1016/j.jmir.2016.05.001. Epub 2016 Jun 20.

PMID:
31047287
30.

Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study.

Eapen LJ, Jones E, Kassouf W, Lambert C, Morgan SC, Moussa M, Nam R, Parliament M, Russell L, Saad F, Siemens DR, Souhami L, Szumacher E, Tyldesley S, Xu Y, Zbieranowski I, Breau RH, Belanger E, Black P, Estey E, Bowan J, Bora B, Brundage M, Chung P, Fleshner N, Evans A, Bauman G, Izawa J, Davidson C, Brimo F.

Can Urol Assoc J. 2016 Mar-Apr;10(3-4):90-4. doi: 10.5489/cuaj.3456.

31.

RE: Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-Related Post-traumatic Stress.

Sepehry AA, Tyldesley S, Davis MK, Simmons C, Rauscher A, Lang DJ.

J Natl Cancer Inst. 2016 Apr 13;108(8). pii: djw048. doi: 10.1093/jnci/djw048. Print 2016 Aug. No abstract available.

32.

Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.

Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, Morgan SC, Tyldesley S, Haluschak JJ, Tan W, Justman S, Jain S.

J Clin Oncol. 2016 Jun 20;34(18):2182-90. doi: 10.1200/JCO.2015.65.7759. Epub 2016 Feb 16.

PMID:
26884580
33.

Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia.

Peacock M, Quirt J, James Morris W, So A, Sing CK, Pickles T, Tyldesley S.

Can Urol Assoc J. 2015 Nov-Dec;9(11-12):409-13. doi: 10.5489/cuaj.3288. Epub 2015 Dec 14.

34.

Rectal Ulcers and Rectoprostatic Fistulas after (125)I Low Dose Rate Prostate Brachytherapy.

Leong N, Pai HH, Morris WJ, Keyes M, Pickles T, Tyldesley S, Wu J; British Columbia Cancer Agency.

J Urol. 2016 Jun;195(6):1811-6. doi: 10.1016/j.juro.2015.12.095. Epub 2016 Jan 14.

PMID:
26778712
35.

Risk of Recurrence or Contralateral Breast Cancer More than 5 Years After Diagnosis of Hormone Receptor-Positive Early-Stage Breast Cancer.

Wilson S, Speers C, Tyldesley S, Chia S, Kennecke H, Ellard S, Lohrisch C.

Clin Breast Cancer. 2016 Aug;16(4):284-90. doi: 10.1016/j.clbc.2015.11.002. Epub 2015 Nov 17.

PMID:
26705158
36.

The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.

Davis MK, Rajala JL, Tyldesley S, Pickles T, Virani SA.

J Oncol. 2015;2015:820403. doi: 10.1155/2015/820403. Epub 2015 Aug 2.

37.

A Quantitative Analysis of the Relationship Between Radiation Therapy Use and Travel Time.

Liu E, Santibáñez P, Puterman ML, Weber L, Ma X, Sauré A, Olivotto IA, Halperin R, French J, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):710-8. doi: 10.1016/j.ijrobp.2015.06.004. Epub 2015 Jun 9.

38.

Using proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience.

Baxter E, Gondara L, Lohrisch C, Chia S, Gelmon K, Hayes M, Davidson A, Tyldesley S.

Curr Oncol. 2015 Jun;22(3):192-8. doi: 10.3747/co.22.2284.

39.

Population-based analysis of the impact and generalizability of the NSABP-B24 study on endocrine therapy for patients with ductal carcinoma in situ of the breast.

Lo AC, Truong PT, Wai ES, Nichol A, Weir L, Speers C, Hayes MM, Baliski C, Tyldesley S.

Ann Oncol. 2015 Sep;26(9):1898-903. doi: 10.1093/annonc/mdv251. Epub 2015 Jun 10.

PMID:
26063632
40.

A comparison of evidence-based estimates and empirical benchmarks of the appropriate rate of use of radiation therapy in ontario.

Mackillop WJ, Kong W, Brundage M, Hanna TP, Zhang-Salomons J, McLaughlin PY, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):1099-107. doi: 10.1016/j.ijrobp.2014.11.026.

PMID:
25832700
41.

Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation?

Hamilton SN, Tyldesley S, Li D, Olson R, McBride M.

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):977-85. doi: 10.1016/j.ijrobp.2014.12.051.

PMID:
25832690
42.

Patterns of recurrence after low-dose-rate prostate brachytherapy: a population-based study of 2223 consecutive low- and intermediate-risk patients.

Lo AC, Morris WJ, Pickles T, Keyes M, McKenzie M, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):745-51. doi: 10.1016/j.ijrobp.2014.12.014.

PMID:
25752387
43.

Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008.

Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA.

J Clin Oncol. 2015 Jan 1;33(1):65-73. doi: 10.1200/JCO.2014.57.2461. Epub 2014 Nov 24.

PMID:
25422485
44.

Canadian radiation oncologists' opinions regarding peer review: A national survey.

Hamilton SN, Hasan H, Parsons C, Tyldesley S, Howard AF, Bobinski MA, Goddard K.

Pract Radiat Oncol. 2015 Mar-Apr;5(2):120-6. doi: 10.1016/j.prro.2014.06.002. Epub 2014 Jul 24.

PMID:
25413408
45.

Incidence of second malignancies in prostate cancer patients treated with low-dose-rate brachytherapy and radical prostatectomy.

Hamilton SN, Tyldesley S, Hamm J, Jiang WN, Keyes M, Pickles T, Lapointe V, Kahnamelli A, McKenzie M, Miller S, Morris WJ.

Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):934-41. doi: 10.1016/j.ijrobp.2014.07.032. Epub 2014 Sep 17.

PMID:
25240272
46.

Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance.

Chung P, Daugaard G, Tyldesley S, Atenafu EG, Panzarella T, Kollmannsberger C, Warde P.

Cancer Med. 2015 Jan;4(1):155-60. doi: 10.1002/cam4.324. Epub 2014 Sep 19.

47.

Long-term mortality from cardiac causes after adjuvant hypofractionated vs. conventional radiotherapy for localized left-sided breast cancer.

Chan EK, Woods R, Virani S, Speers C, Wai ES, Nichol A, McBride ML, Tyldesley S.

Radiother Oncol. 2015 Jan;114(1):73-8. doi: 10.1016/j.radonc.2014.08.021. Epub 2014 Sep 13.

PMID:
25227961
48.

Should women younger than 40 years of age with invasive breast cancer have a mastectomy? 15-year outcomes in a population-based cohort.

Cao JQ, Truong PT, Olivotto IA, Olson R, Coulombe G, Keyes M, Weir L, Gelmon K, Bernstein V, Woods R, Speers C, Tyldesley S.

Int J Radiat Oncol Biol Phys. 2014 Nov 1;90(3):509-17. doi: 10.1016/j.ijrobp.2014.06.041. Epub 2014 Sep 3.

PMID:
25194665
49.

Radical trimodality therapy for patients with locally advanced bladder cancer: The British Columbia Cancer Agency experience.

Baxter E, Dennis K, Kollmannsberger C, Black P, Attwell A, Morris WJ, Tyldesley S.

Urol Oncol. 2015 Feb;33(2):66.e13-9. doi: 10.1016/j.urolonc.2014.07.009. Epub 2014 Aug 29.

PMID:
25168459
50.

Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance.

Kollmannsberger C, Tandstad T, Bedard PL, Cohn-Cedermark G, Chung PW, Jewett MA, Powles T, Warde PR, Daneshmand S, Protheroe A, Tyldesley S, Black PC, Chi K, So AI, Moore MJ, Nichols CR.

J Clin Oncol. 2015 Jan 1;33(1):51-7. doi: 10.1200/JCO.2014.56.2116. Epub 2014 Aug 18.

PMID:
25135991

Supplemental Content

Loading ...
Support Center